Earnings Call · Q2 FY2024·2024-07-25

Q2 24EPS +10.00%·Rev n/aQ1 24EPS -11.90%·Rev n/aQ4 23EPS +53.57%·Rev n/aQ3 23EPS +13.33%·Rev n/a⚠ consensus missing

Indivior Pharmaceuticals, Inc. INDV

Jason Thompson — Unclear, likely Investor Relations or Communications

Mark Crossley — Chief Executive Officer

Ryan Preblick — Chief Financial Officer

+20.3%1d on move date+20.8% vs SPY3d+19.9%5d+26.4%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more INDV calls or request research access.

More INDV calls Browse calls Request research access